N
Noel Milpied
Researcher at Université Bordeaux Segalen
Publications - 306
Citations - 15514
Noel Milpied is an academic researcher from Université Bordeaux Segalen. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 59, co-authored 301 publications receiving 14196 citations. Previous affiliations of Noel Milpied include French Institute of Health and Medical Research & Helsinki University Central Hospital.
Papers
More filters
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Journal ArticleDOI
Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis
David W. Denning,Patricia Ribaud,Noel Milpied,Denis Caillot,Raoul Herbrecht,Eckhard Thiel,Andrea Haas,Markus Ruhnke,Hartmut Lode +8 more
TL;DR: Voriconazole is efficacious in treating acute IA and is proven and probable in 68 patients, and good responses were seen in 60% of those with pulmonary or tracheobronchial IA and 26% of allogeneic stem cell transplant recipients.
Journal ArticleDOI
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Michael Pfreundschuh,Evelyn Kuhnt,Lorenz Trümper,Anders Österborg,Marek Trneny,Lois E. Shepherd,Devinder Gill,Jan Walewski,Ruth Pettengell,Ulrich Jaeger,Pier Luigi Zinzani,Ofer Shpilberg,Stein Kvaløy,Peter de Nully Brown,Rolf A. Stahel,Noel Milpied,Armando López-Guillermo,Viola Poeschel,Sandra Grass,Markus Loeffler,Niels Murawski +20 more
TL;DR: Rituximab added to six cycles of CHOP-like chemotherapy improved long-term outcomes for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows a more refined therapeutic approach to these patients than does assessment by IPI alone.
Journal ArticleDOI
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
Philippe Colombat,Gilles Salles,Nicole Brousse,Pitahey Eftekhari,Piere Soubeyran,Vincent Delwail,Eric Deconinck,Corinne Haioun,Charles Foussard,Catherine Sebban,Astasia Stamatoullas,Noel Milpied,François Boué,Bruno Taillan,Pierre Lederlin,Albert Najman,Catherine Thieblemont,François Montestruc,Anne Mathieu-Boué,Aziz Benzohra,Philippe Solal-Celigny +20 more
TL;DR: Rituximab has a high clinical activity and a low toxicity and induces a high complete molecular response rate in patients with follicular lymphoma and alow tumor burden and is highly correlated with progression-free survival.
Journal ArticleDOI
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
Sylvain Choquet,Véronique Leblond,Raoul Herbrecht,Gérard Socié,Anne-Marie Stoppa,Peter Vandenberghe,Alain Fischer,Franck Morschhauser,Gilles Salles,Walter Feremans,Etienne Vilmer,Marie-Noëlle Peraldi,Philippe Lang,Yvon Lebranchu,Eric Oksenhendler,Jeanne Luce Garnier,Thierry Lamy,Arnaud Jaccard,Augustin Ferrant,Fritz Offner,Olivier Hermine,Anne Moreau,Samira Fafi-Kremer,Patrice Morand,Lucienne Chatenoud,Nathalie Berriot-Varoqueaux,Loïc Bergougnoux,Noel Milpied +27 more
TL;DR: It is concluded that rituximab is effective and safe in PTLD, with stable responses at 1 year, and the response rate and overall survival might be improved by combining ritUXimab with other treatments.